1,919 件 ・ 関連度順
概要と使いどころ
Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA therapy and asking 'Which MRA should I prescribe?' or considering switching agents due to adverse effects, cost, or need for potassium supplementation.
日本語の概要は準備中です。原文の説明を表示しています。
This skill outlines monitoring of mineralocorticoid replacement in primary adrenal insufficiency, focusing on clinical assessment of salt craving, postural hypotension, or edema alongside serum electrolyte measurements. It is initiated when evaluating patients on fludrocortisone therapy to ensure adequate dosing and avoid over- or under-replacement.
日本語の概要は準備中です。原文の説明を表示しています。
Calculates the lowest effective glucocorticoid dose (dexamethasone or prednisone) to normalize blood pressure and serum potassium in glucocorticoid-remediable aldosteronism (GRA/FH-I) by titrating to biochemical and clinical targets. Indicated when initiating medical treatment for confirmed GRA, triggered by findings such as early-onset hypertension, family history of stroke before age 40, spontaneous hypokalemia, or suppressed plasma renin activity with elevated aldosterone.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends correcting serum potassium to the laboratory reference range and repeating aldosterone-to-renin ratio (ARR) screening when the initial screen is negative in a hypertensive patient with hypokalemia. Use when a clinician encounters a negative PA screen in a hypertensive patient with hypokalemia and wonders whether to repeat testing after potassium repletion.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends spironolactone as first-line mineralocorticoid receptor antagonist for initial medical therapy of primary aldosteronism due to low cost and widespread availability. Use when a clinician queries which MRA to start for a patient with PA requiring medical therapy.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends initiating hydrocortisone replacement at a total starting dose of 8 mg/m2 body surface area per day, given in three or four divided doses, for children with confirmed primary adrenal insufficiency (PAI). Use when starting glucocorticoid therapy in pediatric PAI patients, adjusting the dose according to individual clinical response, growth, and need for stress coverage.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends initiating glucocorticoid therapy in all patients with confirmed primary adrenal insufficiency (PAI). Use when PAI diagnosis is confirmed by subnormal cortisol response to ACTH stimulation test or elevated ACTH with low cortisol.
日本語の概要は準備中です。原文の説明を表示しています。
Suggests genetic counseling for patients with primary adrenal insufficiency (PAI) when a monogenic disorder is suspected. Use when PAI patient presents with early-onset disease, syndromic features, consanguinity, family history, or negative autoimmune antibodies.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends initiating fludrocortisone 50–100 µg daily for mineralocorticoid replacement in adults with confirmed aldosterone deficiency (e.g., low aldosterone, elevated renin) and no salt restriction. Use when aldosterone deficiency is confirmed in a patient with primary adrenal insufficiency (PAI) presenting with salt craving or postural hypotension.
日本語の概要は準備中です。原文の説明を表示しています。
Initiates a 6‑month trial of DHEA replacement in women with primary adrenal insufficiency (PAI) who have persistent low libido, depressive symptoms, or low energy despite otherwise optimized glucocorticoid and mineralocorticoid therapy. If the patient does not report a sustained beneficial effect after 6 months, discontinue DHEA.
日本語の概要は準備中です。原文の説明を表示しています。
Suggests using hydrocortisone 15–25 mg or cortisone acetate 20–35 mg daily in two or three divided oral doses for adult primary adrenal insufficiency (PAI) patients initiating glucocorticoid replacement. The highest dose is given upon awakening, with the second dose either early afternoon (≈2 h after lunch) or split into lunch and afternoon doses; consider total daily dose calculation based on chosen formulation and frequency.
日本語の概要は準備中です。原文の説明を表示しています。
Suggests testing HPA axis functionality before and after starting GH replacement in patients not receiving glucocorticoid replacement with apparently normal pituitary-adrenal function. Triggers include initiating GH replacement in a GHD patient who is not on glucocorticoids and has normal adrenal function.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends measuring serum cortisol levels at 8–9 AM as the first-line test for diagnosing central adrenal insufficiency. Use when starting diagnostic workup for suspected adrenal insufficiency; triggers include suspected adrenal insufficiency requiring initial cortisol testing.
日本語の概要は準備中です。原文の説明を表示しています。
In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends hydrocortisone replacement dosing of 15–20 mg total daily, administered as a single dose or divided doses with the highest dose given in the morning upon awakening and the second dose in the afternoon (two-dose regimen) or second and third doses at lunch and late afternoon (three-dose regimen). Use when initiating glucocorticoid replacement for adrenal insufficiency; triggers include diagnosing adrenal insufficiency requiring glucocorticoid replacement.
日本語の概要は準備中です。原文の説明を表示しています。
Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.
日本語の概要は準備中です。原文の説明を表示しています。
Order and interpret lipoprotein(a) [Lp(a)] measurement at least once in a lifetime, apply the risk-enhancer threshold (≥125 nmol/L or ≥50 mg/dL), and run cascade screening of first-degree relatives for premature ASCVD, familial hypercholesterolaemia, or elevated Lp(a) per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 lifetime measurement, how elevated Lp(a) affects LLT initiation and intensification, the cascade screening indications, the interaction of Lp(a) with ASCVD risk estimation, and current therapeutic limitations. Use when a clinician asks when to check Lp(a), how often to repeat Lp(a), elevated Lp(a) what next, treatment for high Lp(a), should I screen my patient's family, Lp(a) and statins, cascade screening indications. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.
日本語の概要は準備中です。原文の説明を表示しています。
This skill suggests initiating antihypertensive treatment while continuing fludrocortisone when blood pressure remains uncontrolled after fludrocortisone dose reduction. Trigger phrases include "BP remains uncontrolled," "persistent hypertension," or "elevated BP despite fludrocortisone adjustment."
日本語の概要は準備中です。原文の説明を表示しています。
Guides comorbidity-stratified selection of initial and further glucose-lowering medicines for adults with type 2 diabetes using the NICE NG28 (2026) framework, covering six clinical profiles: no relevant comorbidity, heart failure, atherosclerotic cardiovascular disease, early onset, obesity, chronic kidney disease, and frailty.
日本語の概要は準備中です。原文の説明を表示しています。
Drift check between the baseline implementation on disk and the claims in `docs/init/seed.md` + cross-references in CLAUDE.md, README.md, and the rendered docs site. Verifies hook/agent/skill/command names + counts, settings.json wiring, project.json key presence, .mcp.json servers, vendored license files, and helper script presence. Exit 0 PASS / 1 FAIL — suitable for CI. Read-only; safe to invoke any time.
日本語の概要は準備中です。原文の説明を表示しています。
Drive a live browser on a scraped page: click, fill forms, log in, paginate, infinite-scroll. Use when content requires interaction or a scrape failed or returned incomplete content.
日本語の概要は準備中です。原文の説明を表示しています。
Autonomous experiment loop that optimizes any file by a measurable metric. Inspired by Karpathy's autoresearch. The agent edits a target file, runs a fixed evaluation, keeps improvements (git commit), discards failures (git reset), and loops indefinitely. Use when: user wants to optimize code speed, reduce bundle/image size, improve test pass rate, optimize prompts, improve content quality (headlines, copy, CTR), or run any measurable improvement loop. Requires: a target file, an evaluation command that outputs a metric, and a git repo.
日本語の概要は準備中です。原文の説明を表示しています。
Build container-based Foundry Agents with Azure AI Projects SDK (ImageBasedHostedAgentDefinition). Use when creating hosted agents with custom container images in Azure AI Foundry.
日本語の概要は準備中です。原文の説明を表示しています。
Adds Wasp knowledge, LLM-friendly documentation fetching instructions, and best practices to your project's CLAUDE.md or AGENTS.md file
日本語の概要は準備中です。原文の説明を表示しています。